Document Detail


Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
MedLine Citation:
PMID:  2151277     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since March 1987, 304 evaluable patients with stage C and D prostate cancer have been entered into a prospective trial comparing Zoladex and Zoladex plus flutamide. To date, there has been no significant difference in over-all and progression-free survival between the 2 treatment groups. However, combined treatment produced a higher response rate (particularly in stage D patients) and a more rapid normalization of abnormal prostatic acid phosphatase levels. In addition, more prompt relief of bone pain was evident in the Zoladex plus flutamide group. However, significantly more side-effects were associated with combined treatment. These findings should be considered with caution because they form an interim analysis, and follow-up time is short. The results do suggest, however, that there is no particular advantage in using a combination of Zoladex plus flutamide compared to adding flutamide on failure of treatment with Zoladex alone.
Authors:
F Boccardo; A Decensi; D Guarneri; A Rubagotti; F Oneto; G Martorana; L Giuliani; U Delli Ponti; S Petracco; P Cortellini
Related Documents :
20739777 - Clinically effective ck-mb reporting: how to do it?
1720287 - Three predominant prostatic proteins.
6195797 - Serum acid phosphatase elevation associated with transurethral resection syndromes.
65817 - Microscopic foci of cancer in prostatectomy for benign disease: diagnostic and surgical...
11433417 - Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist ter...
21206167 - Aberrant β-catenin expression in the histologic differentiation of oral squamous cell ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  European urology     Volume:  18 Suppl 3     ISSN:  0302-2838     ISO Abbreviation:  Eur. Urol.     Publication Date:  1990  
Date Detail:
Created Date:  1991-06-28     Completed Date:  1991-06-28     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  48-53     Citation Subset:  IM    
Affiliation:
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Bone Neoplasms / secondary
Buserelin / administration & dosage,  adverse effects,  analogs & derivatives
Flutamide / administration & dosage
Follow-Up Studies
Goserelin
Humans
Male
Neoplasm Staging
Prostatic Neoplasms / drug therapy*,  mortality,  pathology
Survival Rate
Chemical
Reg. No./Substance:
13311-84-7/Flutamide; 57982-77-1/Buserelin; 65807-02-5/Goserelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinom...
Next Document:  Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multic...